Search details
1.
Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer.
Radiology
; 311(2): e231879, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38771185
2.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(6): 597-610, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37269841
3.
Urinary excretion kinetics of [177Lu]Lu-PSMA-617.
Eur J Nucl Med Mol Imaging
; 50(12): 3572-3575, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37421427
4.
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Eur J Nucl Med Mol Imaging
; 50(7): 1906-1918, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36813980
5.
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.
Eur J Nucl Med Mol Imaging
; 49(2): 460-469, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34218300
6.
[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates.
Eur J Nucl Med Mol Imaging
; 49(13): 4736-4747, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-35930033
7.
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment.
Eur J Nucl Med Mol Imaging
; 49(4): 1101-1112, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34623453
8.
89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
Eur J Nucl Med Mol Imaging
; 49(6): 2064-2076, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34932154
9.
Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer.
Eur J Nucl Med Mol Imaging
; 48(4): 1211-1218, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33025093
10.
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
BMC Cancer
; 20(1): 884, 2020 Sep 14.
Article
in English
| MEDLINE | ID: mdl-32928177
11.
Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy.
Q J Nucl Med Mol Imaging
; 64(3): 250-264, 2020 Sep.
Article
in English
| MEDLINE | ID: mdl-32744039
12.
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer.
Q J Nucl Med Mol Imaging
; 63(3): 235-252, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31298014
13.
Diagnostic accuracy of 18F-FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma.
BMC Cancer
; 17(1): 887, 2017 12 22.
Article
in English
| MEDLINE | ID: mdl-29273015
14.
Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany.
Endocr Pract
; 21(2): 122-7, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25297668
15.
Impact of dual-energy CT prior to radioembolization (RE).
Acta Radiol
; 56(11): 1293-9, 2015 Nov.
Article
in English
| MEDLINE | ID: mdl-25398776
16.
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.
Eur J Nucl Med Mol Imaging
; 41(3): 505-10, 2014 Mar.
Article
in English
| MEDLINE | ID: mdl-24196919
17.
Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT.
Eur J Nucl Med Mol Imaging
; 41(1): 79-88, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24085502
18.
The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease.
J Nucl Med
; 2024 Feb 15.
Article
in English
| MEDLINE | ID: mdl-38360048
19.
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT.
EJNMMI Phys
; 11(1): 34, 2024 Apr 03.
Article
in English
| MEDLINE | ID: mdl-38568428
20.
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
J Nucl Med
; 65(4): 541-547, 2024 Apr 01.
Article
in English
| MEDLINE | ID: mdl-38423781